Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9579283 | 0.90 | KCNH2 (0.40) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL5265112 | 0.90 | KCNH2 (0.40) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL128172 | 0.89 | HRH3 (0.31) | HTR1ADRD3 | |
| SCHEMBL28199223 | 0.86 | HRH3 (0.30) | — | |
| SCHEMBL128051 | 0.86 | — | — | |
| SCHEMBL5405932 | 0.85 | KCNH2 (0.48) | KCNH2KDM5AKDM4CPLA2G1BPLA2G2A | |
| SCHEMBL5398325 | 0.85 | KCNH2 (0.48) | KCNH2KDM5AKDM4CPLA2G1BPLA2G2A | |
| SCHEMBL5262504 | 0.84 | CA12 (0.34) | KCNH2KDM5AKDM4CNPSR1 | |
| SCHEMBL23451742 | 0.83 | NPSR1 (0.38) | KCNH2CHRM2HTR1AADRA2ACHRM1 | |
| SCHEMBL736317 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1717230-B1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2014-08-06 | — | — | EP | disclosed |
| US-8461375-B2 | Method for the continuous production of alkyl(meth)acrylates with multiple catalyst recycling | EVONIK RÖHM GMBH (DE) | 2013-06-11 | — | — | US | disclosed |
| EP-1583733-B1 | IMPROVED METHOD FOR THE CONTINUOUS PRODUCTION OF ALKYL(METH)ACRYLATES WITH MULTIPLE CATALYST RECYCLING | EVONIK ROEHM GMBH (DE) | 2013-04-24 | — | — | EP | disclosed |
| EP-1399409-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF SE (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-8268842-B2 | Fused ring 4-oxopyrimidine derivative | MSD K.K. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8163770-B2 | Benzoxathiin derivative | MSD. K. K. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8138206-B2 | Piperidine derivative | MSD. K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20100168156-A1 | Novel Benzoxathiine Derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-7645756-B2 | 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| WO-2002100814-A1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002100815-A1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 2002-12-19 | — | — | WO | disclosed |
| US-5981557-A | HAVING IMPROVING EFFECTS ON THE DYSMOTILITY IN THE GASTROINTESTINAL TRACT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0870765-A1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| EP-0450066-B1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5401740-A | FOR INHIBITING PLATELET AGGREGATION | OTSUKA PHARMACEUTICAL CO. (JP) | 1995-03-28 | — | — | US | disclosed |
| US-5227381-A | Anticoagulant | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-13 | — | — | US | disclosed |
| EP-0450066-A1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-09 | — | — | EP | disclosed |
| US-3985755-A | ANTHELMINTIC AGENTS AND DISINFECTANTS | E. R. SQUIBB & SONS, INC. (US) | 1976-10-12 | — | — | US | disclosed |
| US-3983130-A | ANTHELMINTICS, DISINFECTANTS | E. R. SQUIBB & SONS, INC. (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168156-A1 | Novel Benzoxathiine Derivative | XDH, GPR119, BRIX1 | KCNH2 2702/4885CHRM2 570/4885HTR1A 1589/4885 |
| US-20090209562-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | KCNH2 299/4885CHRM2 89/4885HTR1A 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.